Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma

Project Oncology®

Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

12d ago

MP3•Episode home

Host: Jesus G. Berdeja, MD
Guest: Nicholas G. Barkemeyer, MPAS
Guest: Ajai Chari, MD
Guest: Harvey Church
Guest: Amy Gebhardt
Guest: Steven Morrow
This activity is not accredited for CME/CE credit.

This episode of Myeloma Matters features discussions of bispecific antibody therapy, a powerful form of targeted immunotherapy that has produced high response rates and helped patients—even those with multiply relapsed or refractory multiple myeloma (RRMM)—achieve deeper and more sustained responses. This podcast will also review strategies for preventing and managing the serious, potentially life-threatening, adverse events (AEs) associated with myeloma bispecific antibody therapy, which include cytokine release syndrome (CRS), neurotoxicity, and infection.

158 episodes

#Oncology #Obstetrics And Gynecology #Oncology And Hematology #Omnia Education #Cme/ce #Oncology Power Hour #ReachMD #Women's Health #Women's Health Fridays™ #Science #Medicine #Health and Well-Being #Project Oncology®